The global iron-deficiency anemia therapy market is experiencing significant growth, driven by the increasing prevalence of iron-deficiency anemia (IDA) due to factors such as insufficient dietary iron intake and malabsorption issues. This condition, characterized by a lack of adequate healthy red blood cells, affects a substantial portion of the global population, particularly women and children. Therapeutic approaches primarily include oral and parenteral iron supplementation, with oral iron therapy being the most commonly prescribed due to its convenience and cost-effectiveness. However, parenteral iron therapy is gaining traction, especially in cases where rapid replenishment of iron stores is necessary or when oral supplementation is ineffective or not tolerated. The market is also witnessing advancements in drug formulations aimed at improving efficacy and reducing side effects. Geographically, regions with higher prevalence rates of IDA, such as parts of Africa and Southeast Asia, represent significant markets for these therapies. Concurrently, developed regions are experiencing growth due to increased awareness, routine screening, and proactive management of anemia. Overall, the iron-deficiency anemia therapy market is poised for continued expansion, driven by ongoing research, product innovation, and a global emphasis on addressing nutritional deficiencies.
Global Iron-Deficiency Anemia Therapy Market size was valued at USD 5.35 billion in 2024 and is projected to reach USD 11.46 billion by 2032, with a CAGR of 10.0% during the forecast period of 2025 to 2032.
To know more, visit https://www.databridgemarketresearch.com/reports/global-iron-deficiency-anemia-therapy-market
Below are the Top Iron-Deficiency Anemia Therapy Companies with a Significant Market Share:
|
Rank
|
Company
|
Overview
|
Product Portfolio
|
Sales Geographical Coverage
|
Developments
|
|
1.
|
Vifor Pharma Ltd.
|
Vifor Pharma Ltd. is a global leader in iron deficiency and nephrology therapies. The company specializes in developing and commercializing treatments for iron-deficiency anemia, chronic kidney disease (CKD), and rare diseases. Vifor Pharma is known for its intravenous iron therapy products, including Ferinject/Injectafer, a widely used iron replacement therapy. The company was acquired by CSL Limited in 2022, further strengthening its global footprint in hematology and iron deficiency treatments.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In March 2024, Vafseo approved by the U.S. FDA for the treatment of anemia due to chronic kidney disease in dialysis-dependent adult patients. CSL Vifor is pleased that its partner Akebia Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Vafseo (vadadustat) tablets for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) developed by Akebia.
|
|
2.
|
DAIICHI SANKYO COMPANY, LIMITED
|
Daiichi Sankyo is a multinational pharmaceutical company focused on innovative medicines in oncology, cardiovascular, and rare diseases. In the iron-deficiency anemia market, the company offers Injectafer® (Ferric Carboxymaltose) and other iron supplements used globally. Its commitment to research and development has positioned it as a key player in addressing iron-related disorders and anemia management.
|
|
North America, South America, Asia-Pacific, and Europe
|
In October 2019, DAIICHI SANKYO COMPANY, LIMITED has announced plans to install a 3.3 megawatt onsite solar power system at its Onahama Plant in Fukushima, Japan, which will be among the largest in the country's pharmaceutical sector. This initiative will increase the company's sustainability efforts and reduce its carbon footprint by generating a significant portion of the plant's electricity needs from renewable sources.
|
|
3.
|
AFT Pharmaceuticals
|
AFT Pharmaceuticals is a fast-growing pharmaceutical company that develops and distributes prescription and over-the-counter (OTC) medicines across multiple therapeutic areas. In the iron-deficiency anemia sector, AFT is known for its Ferro-Sachets®, an oral iron supplement designed to improve iron absorption with minimal side effects. The company operates in New Zealand, Australia, Southeast Asia, and the Middle East, focusing on high-quality, patient-centric treatments.
|
Ferro-liquid
|
Australia, New Zealand, South East Asia, Europe
|
|
|
4.
|
Sanofi
|
Sanofi is a global pharmaceutical giant engaged in research, development, and manufacturing of innovative healthcare solutions. It provides a range of treatments for iron-deficiency anemia, including Maltofer and Venofer, which are widely used oral and intravenous iron supplements. Sanofi’s expertise spans across pharmaceuticals, vaccines, and specialty care, making it a dominant force in global healthcare markets.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In April 2024, Rilzabrutinib which is a BTK (Bruton's tyrosine kinase) inhibitor indicated for warm autoimmune hemolytic anemia is in the second phase of drug trial.
|
|
5.
|
Pfizer Inc
|
Pfizer is one of the world's leading pharmaceutical companies, known for its extensive portfolio in oncology, cardiovascular diseases, rare diseases, and vaccines. In the iron-deficiency anemia market, Pfizer develops and distributes advanced iron replacement therapies, including intravenous iron formulations. With a strong global presence and extensive R&D investments, Pfizer continues to play a crucial role in advancing anemia treatments.
|
|
North America, South America, Middle East and Africa, Asia-Pacific, and Europe
|
In November 2023, Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting and presented its latest data showcasing advances in the treatment of hemophilia, sickle cell disease, and blood cancers at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego from December 9-12.
|
Conclusion
The global iron-deficiency anemia therapy market is expected to see steady growth as the prevalence of the condition remains high, particularly among vulnerable populations such as women and children. With increasing awareness, routine screening, and improved access to healthcare, both developing and developed regions are driving demand for effective treatments. While oral iron supplements remain the primary treatment option due to affordability and convenience, the growing adoption of parenteral iron therapies highlights the need for faster and more efficient solutions in severe cases. Ongoing advancements in drug formulations aimed at enhancing efficacy and minimizing side effects further contribute to market expansion. As research and innovation continue to shape the industry, the market is well-positioned for sustained growth, addressing the global burden of iron-deficiency anemia.
